Viking Therapeutics VKTX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$472.34M-268% | -$359.64M-227% | -$237.39M-139% | -$171.55M-77.3% | -$128.24M-36.8% | ||
| $39.81M+20.3% | $40.82M+37.4% | $37.9M+34.7% | $39.54M+67.4% | $33.08M+56.3% | ||
| -$340.33M-154% | -$278.69M-217% | -$224.58M-202% | -$152.54M-112% | -$133.99M-144% | ||
| $332.33M— | $341.39M— | —— | —— | —— | ||
| $88.17M+1,201% | $76.44M-87.5% | $2.34M-99.6% | $4.38M-99.3% | $6.78M-99.2% | ||
| $84.22M— | $143.19M— | $54.17M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Viking Therapeutics's cash flow data come from?
- Every line is extracted from Viking Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.